{"version":"1.0","type":"link","title":"Locoregional gemcitabine plus surufatinib and camrelizumab in FGFR2-non-altered intrahepatic cholangiocarcinoma.","author_name":"Guo B 외","author_url":"https://prs-insight.online/author/Guo%20B","provider_name":"PRSinsight","provider_url":"https://prs-insight.online","thumbnail_url":"https://prs-insight.online/og/paper/169615","thumbnail_width":1200,"thumbnail_height":630}